Lord Patel (CB)

My Lords, these drugs are relatively new and pretty powerful as GLP-1 and GLP-2 agonists. The important issue is safety: through NHS prescribing and MHRA reporting, we collect data on medium-term and

My Lords, it is a pleasure to follow the noble Lord, Lord Strathclyde, and I thank the noble Baroness, Lady Taylor of Bolton, for introducing her sensible report that introduces retiral. Speaking pers

My Lords, after listening to the last debate, I am tempted to speak only about how health research data might help economic growth to alleviate all the debt that we were talking about, but I will not.

To ask His Majesty’s Government what assessment they have made of the use of patient data for research.

My Lords, can the Minister say in the spring of which year the workforce plan will be published?

My Lords, I will refine the previous questions. Resistant hypertension occurs when the blood pressure does not respond to standard treatment of two, three or even four drugs—hence we call it resistant